Workflow
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
ITCIIntra-Cellular Therapies(ITCI) ZACKS·2024-06-19 15:30

Intra-Cellular Therapies (ITCI) announced positive top-line results from Study 502, the second late-stage study that evaluated lumateperone 42 mg for the treatment of major depressive disorder (MDD). Intra-Cellular also reported that the key secondary endpoint was also achieved by demonstrating a statistically significant and clinically meaningful reduction in the Clinical Global Impression Scale score, which is a measure of severity of illness compared with placebo at week six. Additionally, feedback from ...